Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
5Nevrcs7KN55VZtA
